MedTrace Logo

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

NCT04708236 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2021-06-14

No results posted yet for this study

Summary

Evaluate the safety and effect of ORTD-1 on COVID-19 related pneumonia.

Conditions

Interventions

DRUG

ORTD-1 low dose

ORTD-1 will be administered intravenously once daily for 5 consecutive days.

DRUG

ORTD-1 mid dose

ORTD-1 will be administered intravenously once daily for 5 consecutive days.

DRUG

ORTD-1 high dose

ORTD-1 will be administered intravenously once daily for 5 consecutive days.

OTHER

Vehicle control

Vehicle Control will be administered intravenously once daily for 5 consecutive days.

Sponsors & Collaborators

  • Oryn Therapeutics, LLC

    lead INDUSTRY

Principal Investigators

  • Alpesh Amin, MD · Professor & Chair, Department of Medicine University of California, Irvine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2021-05-31
Completion
2021-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708236 on ClinicalTrials.gov